melanocortin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
HA (aq) + H2O (l) ⇌ H3O+ (aq) + A− (aq) Ka Common examples of monoprotic acids in mineral acids include hydrochloric acid (HCl) and nitric acid (HNO3). On the other hand, for organic acids the term mainly indicates the presence of one carboxylic acid group and sometimes these acids are known as monocarboxylic acid. Examples in organic acids include formic acid (HCOOH), acetic acid (CH3COOH) and benzoic acid (C6H5COOH).
. Special relativity also redefines the concept of mass and energy, which can be used interchangeably and are defined relative to the frame of reference. Several quantities had to be defined for consistency, such as the rest mass of a particle (mass in the rest frame of the particle) and the relativistic mass (in another frame). The latter term is usually less frequently used. In general relativity, conservation of both mass and energy is not globally conserved and its definition is more complicated.
=== Europe === Hardtack, baked with or without the addition of fat, was and still is a staple in Russian military rations, especially in the Navy, as infantry traditionally preferred simple dried bread when long shelf life was needed. Called galeta (галета) in Russian, it is usually somewhat softer and more crumbly than traditional hardtack, as most varieties made in Russia include at least some fat or shortening, making them closer to saltine crackers. One such variety, khlyebtsy armyeyskiye (хлебцы армейские), or "army crackers", is included in Russian military rations. Other brands enjoy significant popularity among the civilian population as well, both among campers and the general populace. In Genoa, hardtack was and still is a traditional addition to a fish and vegetable salad called cappon magro. In Germany, hardtack is included in every military ration and colloquially known as Panzerplatten (armor plates) or Panzerkekse (armor cookies/tank cookies). Due to conscription for many years a large part of the male population knew about them from their service and thus they became somewhat popular even in civilian use. The company that makes them also sells them unaltered to the civilian market. They are said to have many properties, some jokingly assigned, such as the ability to combine them with standard issue shoe polish to create a flammable device, or to glue them onto vehicles to increase their armor protection.
== Goals == The project aims to develop both the methodology and hardware to allow communities and individuals to produce medical-grade insulin for the treatment of diabetes. These methods will be low-cost in order to combat the high price of insulin in places like the US. There is also potential for small-scale distributed production that may allow for improved insulin access in places with poor availability infrastructure. Access to insulin remains so insufficient around the globe that "half of all people who need insulin lack the financial or logistical means to obtain adequate supplies".
Sources: en.wikipedia.org
Unlike translucent nanoemulsions, which require specialized equipment to be produced, microemulsions are spontaneously formed by "solubilizing" oil molecules with a mixture of surfactants, co-surfactants, and co-solvents. The required surfactant concentration in a microemulsion is, however, several times higher than that in a translucent nanoemulsion, and significantly exceeds the concentration of the dispersed phase. Because of many undesirable side-effects caused by surfactants, their presence is disadvantageous or prohibitive in many applications. In addition, the stability of a microemulsion is often easily compromised by dilution, by heating, or by changing pH levels. Common emulsions are inherently unstable and, thus, do not tend to form spontaneously. Energy input – through shaking, stirring, homogenizing, or exposure to powerful ultrasound – is needed to form an emulsion. Over time, emulsions tend to revert to the stable state of the phases comprising the emulsion. An example of this is seen in the separation of the oil and vinegar components of vinaigrette, an unstable emulsion that will quickly separate unless shaken almost continuously. There are important exceptions to this rule – microemulsions are thermodynamically stable, while translucent nanoemulsions are kinetically stable. Whether an emulsion of oil and water turns into a "water-in-oil" emulsion or an "oil-in-water" emulsion depends on the volume fraction of both phases and the type of emulsifier (surfactant) (see Emulsifier, below) present.
The diarrheal type is associated with a wide range of foods, has an 8-to-16-hour incubation time, and is associated with diarrhea and gastrointestinal pain. Also known as the 'long-incubation' form of B. cereus food poisoning, it might be difficult to differentiate from poisoning caused by Clostridium perfringens. Enterotoxin can be inactivated after heating at 56 °C (133 °F) for 5 minutes, but whether its presence in food causes the symptom is unclear, since it degrades in stomach enzymes; its subsequent production by surviving B. cereus spores within the small intestine may be the cause of illness. The 'emetic' form commonly results from rice which is cooked at a time and temperature insufficient to kill any spores present, then improperly refrigerated. The remaining spores can produce a toxin, cereulide, which is not inactivated by later reheating. This form leads to nausea and vomiting 1–5 hours after consumption. Distinguishing from other short-term bacterial foodborne intoxications, such as by Staphylococcus aureus, can be difficult. Emetic toxin can withstand 121 °C (250 °F) for 90 minutes. As a result of the emetic type's association with rice, it is sometimes referred to colloquially as fried rice syndrome. The diarrhetic syndromes observed in patients are thought to stem from the three toxins: hemolysin BL (Hbl), nonhemolytic enterotoxin (Nhe), and cytotoxin K (CytK). The nhe/hbl/cytK genes are located on the chromosome of the bacteria. Transcription of these genes is controlled by PlcR. These genes occur in the taxonomically related B. thuringiensis and B.
=== Generic names === Naltrexone is the generic name of the drug and its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, and DCITTooltip Denominazione Comune Italiana, while naltrexone hydrochloride is its USPTooltip United States Pharmacopeia and BANMTooltip British Approved Name.
== Chemistry == The chemical name is 1-deoxy-1 (methylamino)-D-glucitol, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (salt). The injectable form of delafloxacin is sold as the meglumine salt of the active ingredient and its United States Adopted Name, delafloxacin meglumine, reflects that; the injection formulation also includes EDTA and sulfobutylether-β-cyclodextrin. The tablet is made of delafloxacin, citric acid anhydrous, crospovidone, magnesium stearate, microcrystalline cellulose, povidone, sodium bicarbonate, and sodium phosphate monobasic monohydrate.
== History == The British computer scientist Alan Turing laid the theoretical groundwork for artificial intelligence. His foundational 1936 paper on the Entscheidungsproblem introduced the concept of the universal computing machine. Turing's wartime efforts at Bletchley Park involved developing the Bombe, an electromechanical device that utilized heuristic search techniques to decipher Enigma codes. In 1950, Turing published his seminal paper "Computing Machinery and Intelligence" in the journal Mind, where he proposed the "Imitation Game" (now known as the Turing Test) as a criterion for machine intelligence. This period established Britain as a global leader in early computational theory and machine intelligence. During the 1960s, the UK established AI research centers, most notably at the University of Edinburgh. In 1963, Donald Michie founded a small research group that later evolved into the Department of Machine Intelligence and Perception. Michie's team developed the Freddy robots (Freddy I and Freddy II), which were early examples of robots capable of integrating vision and manipulation to assemble objects. Researchers such as Robert Kowalski at the University of Edinburgh and later Imperial College London made significant contributions to logic programming, laying the theoretical foundations for the Prolog programming language. However, the optimism of the 1960s was curtailed by the 1973 Lighthill Report.
Sources: en.wikipedia.org
==== Photodynamic cancer therapy ==== Various cancer treatments utilizing PDT have been approved by the FDA. Treatments are available for actinic keratosis (blue light with aminolevulinic acid), cutaneous T-cell lymphoma, Barrett esophagus, basal cell skin cancer, esophageal cancer, non-small cell lung cancer, and squamous cell skin cancer (Stage 0). Photosensitizing agents clinically-approved or undergoing clinical trials for the treatment of cancers include Photofrin, Temoporfin, Motexafin lutetium, Palladium bacteriopheophorbide, Purlytin, and Talaporfin. Verteporfin is approved to treat eye conditions such as macular degeneration, myopia, and ocular histoplasmosis. Third-generation photosensitizers are currently in development, but none are yet approved for clinical trials.
== Application fields == Slurry ice is commonly used in a wide range of air conditioning, packaging, and industrial cooling processes, supermarkets, and cooling and storage of fish, produce, poultry and other perishable products.
==== Panama Canal ==== In 2024, Trump demanded that Panama return control of the Panama Canal to the United States because "excessive rates" were being charged for American passage. The United States previously was in control of the Panama Canal Zone from 1903 until 1999, and has invaded Panama before in 1989. Trump told Congress in March 2025 that his administration "will be reclaiming the Panama Canal". Also that month, Defense Secretary Pete Hegseth instructed the Trump administration to "immediately" present "credible military options to ensure fair and unfettered US military and commercial access to the Panama Canal".
Keith G. Harding CBE FRCGP FRCP FRCS FLSW is a British physician. Harding graduated from Birmingham University with an MBChB degree in Medicine in 1976. Harding is the Director of TIME Institute (Translation, Innovation, Methodology and Engagement) and Head of the Wound Healing Research Unit in the School of Medicine at Cardiff University. He is Clinical Lead for Wound Healing in the Cardiff & Vale NHS Trust. In September 2013 Harding was appointed Dean of Clinical Innovation at Cardiff University. From 2002 to 2005 he was Head of the Department of Surgery at Cardiff University. He is Editor-in-Chief of the International Wound Journal. Keith Harding is a Past President of the European Tissue Repair Society. He was the first President of the European Pressure Ulcer Advisory Panel, and first Recorder of the European Wound Management Association. Harding was Chair of the International Working Group on Wound Healing in Diabetic Foot Disease in 2003. He was Chair of the Expert Working Group that produced a range of International Consensus Documents from 2004 to 2011. Professor Harding was appointed a Commander of the Order of the British Empire in the 2013 New Year Honours for services to medicine and healthcare. Harding is a Fellow of the Royal College of General Practitioners, a Fellow of the Royal College of Physicians, and a Fellow of the Royal College of Surgeons. In 2014, Professor Harding was elected a Fellow of the Learned Society of Wales.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.